These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. Reassurance about bioequivalence of generic thyroxine. Feek CM N Z Med J; 1992 Jan; 105(926):21. PubMed ID: 1549275 [No Abstract] [Full Text] [Related]
44. Pharmaceutical quality of generic isotretinoin products, compared with Roaccutane. Taylor PW; Keenan MH Curr Med Res Opin; 2006 Mar; 22(3):603-15. PubMed ID: 16574043 [TBL] [Abstract][Full Text] [Related]
45. Probability of passing dissolution acceptance criteria for an immediate release tablet. Dumont ML; Berry MR; Nickerson B J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465 [TBL] [Abstract][Full Text] [Related]
46. [Generic drug lines: all is not gold that glitters]. Córdoba García R Aten Primaria; 1999 Oct; 24(7):387-9. PubMed ID: 10592545 [No Abstract] [Full Text] [Related]
47. Japanese guidance on bioavailability and bioequivalence. Aoyagi N Eur J Drug Metab Pharmacokinet; 2000; 25(1):28-31. PubMed ID: 11032086 [TBL] [Abstract][Full Text] [Related]
48. "Insight" into drug quality: comparison of simvastatin tablets from the US and Canada obtained via the Internet. Veronin MA; Lee E; Lewis EN Ann Pharmacother; 2007 Jul; 41(7):1111-5. PubMed ID: 17595307 [TBL] [Abstract][Full Text] [Related]
49. [Generic antiarrhythmics: safety and efficacy versus cost]. Katz A; Zalzstein E Harefuah; 2001 Nov; 140(11):1087-90. PubMed ID: 11759388 [No Abstract] [Full Text] [Related]
50. [Generics: authorization to market and quality guarantees]. De Muylder JA Rev Med Brux; 2000 Sep; 21(4):A276-8. PubMed ID: 11068480 [TBL] [Abstract][Full Text] [Related]
51. Quality assurance test of delivered dose uniformity of multiple-dose inhaler and dry powder inhaler drug products. Tsong Y; Dong X; Shen M; Lostritto RT J Biopharm Stat; 2015; 25(2):328-38. PubMed ID: 25357132 [TBL] [Abstract][Full Text] [Related]
52. The generic drug approval process. Rheinstein PH Am Fam Physician; 1993 Dec; 48(8):1357-60. PubMed ID: 8249762 [No Abstract] [Full Text] [Related]
53. Generic immunosuppressants: the European perspective. Christians U Transplant Proc; 1999 May; 31(3A Suppl):19S-22S. PubMed ID: 10330954 [No Abstract] [Full Text] [Related]
54. Analysis of purity profiles of generic lisinopril tablets marketed in Croatia. Benković G; Sokolić M; Cudina B; Zulj RT; Tomić S Coll Antropol; 2013 Jun; 37(2):601-6. PubMed ID: 23941010 [TBL] [Abstract][Full Text] [Related]
55. Generics almost always a better choice. Johns Hopkins Med Lett Health After 50; 2009 Feb; 20(12):6-7. PubMed ID: 19241612 [No Abstract] [Full Text] [Related]
56. Generic drugs. Save money--but is there a cost? Roberts SS Diabetes Forecast; 2002 Nov; 55(11):51-3. PubMed ID: 14768605 [No Abstract] [Full Text] [Related]
58. Initial responses to recommendations of the Blue Ribbon Committee on Generic Medicines. Heller WM Am J Hosp Pharm; 1993 Feb; 50(2):318-22. PubMed ID: 8480792 [No Abstract] [Full Text] [Related]
59. The end of the beginning? Nat Biotechnol; 2006 Apr; 24(4):367. PubMed ID: 16601702 [No Abstract] [Full Text] [Related]
60. Influence of point estimates and study power of bioequivalence studies on establishing bioequivalence between generics by adjusted indirect comparisons. Gwaza L; Gordon J; Potthast H; Welink J; Leufkens H; Stahl M; García-Arieta A Eur J Clin Pharmacol; 2015 Sep; 71(9):1083-9. PubMed ID: 26105964 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]